___

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.

2. Lin YR, Wei XH, Uhlman M, Lin XT, Wu SF, Diao PF, et al. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml-1 and 10.1–20.0 ng ml-1: a multicenter study. Asian J Androl 2015; 17: 503-7.

3. Tang P, Jin XL, Uhlman M, Lin YR, Deng XR, Wang B, et al. Prostate volume as an independent predictor of prostate cancer in men with PSA of 10– 50 ng ml− 1. Asian J Androl 2013; 15: 409-12.

4. Kehinde EO, Sheikh M, Mojimoniyi OA, Francis I, Anim JT, Nkansa‐Dwamena D, et al. High serum prostate‐specific antigen levels in the absence of prostate cancer in Middle‐Eastern men: the clinician's dilemma. BJU Int 2003; 91: 618-22.

5. Selmy, G. The Value of Transrectal Ultrasonography (TRUS) in the Urosonographic Unit. , Afr J Urol 1998; 4: 93-7.

6. Toktas G, Unluer E, Aglamis E, Kulksizoglu H, Mimaroglu S. Effects of chronic prostatitis on prostate specific antigen. BJU Int 2000; 86: 104.

7. Tan YH, Tan KY, Foo KT. The role of a trial of antibiotics in asymptomatic patients with elevated prostate specific antigen–an Asian perspective. BJU Int 2000; 86: 104.

8. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006; 98:529–534.

9. Tang P, Chen H, Uhlman M, Lin YR, Deng XR, Wang B, et al. A nomogram based on age, prostatespecific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl 2013; 15: 129-33.

10. Xu D, Yu Y, Zhu Y, Huang T, Chen Y, Qi J. A new model consists of intravesical prostatic protrusion, prostate volume and serum prostaticspecific antigen in the evaluation of prostate cancer. Pathol Oncol Res 2014: 20: 439-43.

11. Baltaci S, Aksoy H, Türkölmez K, Elhan AH, Özden E, Gogus O. Use of percent free prostatespecific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostatespecific antigen levels. Urol Int 2003; 70: 36-41.

12. Sakai I, Harada K, Hara I, Eto H, Miyake H. Limited usefulness of the free-to-total prostatespecific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men. Int J Clin Oncol 2004; 9: 64–67.

13. Segawa N, Gohji K, Iwamoto Y, Ueda H, Katsuoka Y. Prostate cancer detection by prostatespecific antigen-related parameters. Hinyokika Kiyo 2003; 49: 405–410.

14. Rodriguez-Patron RR, Mayayo DT, Gonzalez GA, Zuccarino AL, Garcia GR, Cuesta RC. Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy. Arch Esp Urol 2002; 55: 225–34.

15. Ozdal OL, Aprikian AG, Begin LR, Behlouli H, Tanguay S. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int 2004; 93: 70–4.

16. Martinez-Pineiro L, Mediero JG, Gancedo PG, Tabernero A, Lozano D, Lopez-Tello JJ, et al. Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4–10 ng/ml. World J Urol 2004; 22: 124-31.

17. Djavan B, Zlotta AR, Remzi M, Ghawidel K, Bursa B, Hruby S, et al. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology 1999; 54: 846-52.

Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60.

19. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, et al. The ratio of prostate‐specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of< 4 ng/mL. Cancer 2005; 104: 993-1003.

20. Ohori M, Dunn JK, Scardino PT. Is prostatespecific antigen density more useful than prostatespecific antigen levels in the diagnosis of prostate cancer? Urology 1995; 46: 666 -71.

21. Bazinet M, Meshref AW, Trudel C, Aronson S, Péloquin F, Nachabe M, et al. Prospective evaluation of prostate-specificantigen density and systematicbiopsies for early detection of prosttic carcinoma. Urology 1994; 43: 44-51.

22. Ciatto S, Bonardi R, Lombardi C, Cappelli G, Castagnoli A, D'Agata A, et al. Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a populationbased screening setting. , Int J Biol Markers 2001; 16: 179-82.

23. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185: 471–6.

24. Kuriyama M, Uno H, Watanabe H, Yamanaka H, Saito Y, Shida K. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol 1999; 29: 617–22.

25. Al-Khalil S, Boothe D, Durdin T, Sunkara S, Watkins P, Yang S, et al. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review. , Int Urol Nephrol 2016; 48: 91-7.

26. Erdogan A, Polat S, Keskin E, Turan A. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5–10 ng/mL and 10.1–30 ng/mL?. Aging Male 2019; 1-7.

27. Kobayashi T, Mitsumori K, Kawahara T, Nishizawa K, Ogura K, Ide, Y. Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate‐specific antigen levels of 2.0– 10.0 ng/mL. Int J Urol 2005; 12: 969-75.

28. Shigemura K, Arakawa S, Yamanaka K, Yasui N, Matsubara S, Iwamoto T, et al. Potential predictive factors of positive prostate biopsy in the Japanese population. Int Urol Nephrol 2008; 40: 91-6.

29. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002; 48: 1279-1287.

30. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce falsepostitive PSA results in prostate cancer screening. Int J Cancer 2004; 111: 310–5.

31. Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012; 61: 577–83.

32. Ankerst DP, Till C, Boeck A, Goodman PJ, Tangen CM, Thompson, et al. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology 2013; 82: 1076-82.

33. Neves JB, Emberton M, Kasivisvanathan V. Management of an Elevated PSA and Biopsy Strategies in the Large Prostate. In: The Big Prostate. Springer, Cham 2018; 41-51.

34. Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ. Prostate cancer detection: relationship to prostate size. Urology 1999; 53: 764-8.

35. Marks LS, Roehrborn CG, Wolford E, Wilson TH. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J Urol 2007; 177: 1408-13.

36. Arivazhagan J, Nandeesha H, Dorairajan LN, Sreenivasulu K. Association of elevated interleukin17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. The Aging Male 2017; 20: 115- 8.

37. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostatespecific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. Jama 1993; 270: 860-4.

38. Bruno JJ, Armenakas NA, Fracchia JA. Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml. J Urol 2007; 177: 741-4.

39. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms ofserum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997; 24: 353–365.

40. Gorski A, Rouprêt M, Peyronnet B, et al. Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. J Urol 2015; 194: 669-73.